3rd Quarter - Report

EPILEPSY FOUNDATION for EPILEPSY FOUNDATION

Period 3rd Quarter 2018 Filed Oct 19, 2018 Signed by Abbey Roudebush

Official filing
Firm
EPILEPSY FOUNDATION
Client
EPILEPSY FOUNDATION
Income
—
Expenses
$80,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Civil Rights/Civil Liberties CIV

-H.R. 620, ADA Education and Reform Act, oppose passage.

LobbyistCovered position, as disclosed
ABBEY ROUDEBUSH New —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); White House Office; SENATE

Bills named: H.R. 620 (115th)

Health Issues HCR

-S. 2553, Know the Lowest Price Act of 2018, support passage. -S. 2554, Patient Right to Know Drug Prices Act, support passage. -H.R. 2077, Restoring the Patient's Voice Act, support passage.

LobbyistCovered position, as disclosed
ABBEY ROUDEBUSH New —

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA)

Bills named: H.R. 2077 (115th), S. 2554 (115th), S. 2553 (115th)

Budget/Appropriations BUD

--H.R. 6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019, support funding for the National Institutes of Health, Centers for Disease Control & Prevention, Special Projects of Regional and National Significance and the National Neurological Conditions Surveillance System.

LobbyistCovered position, as disclosed
ABBEY ROUDEBUSH New —

Contacted: Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Food & Drug Administration (FDA)

Bills named: H.R. 6157 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.